Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.

PubWeight™: 1.70‹?› | Rank: Top 3%

🔗 View Article (PMID 26228081)

Published in Parkinsonism Relat Disord on July 10, 2015

Authors

Paola Costa-Mallen1, Cyrus P Zabetian2, Pinky Agarwal3, Shu-Ching Hu4, Dora Yearout5, Ali Samii2, James B Leverenz6, John W Roberts7, Harvey Checkoway8

Author Affiliations

1: Bastyr University Research Institute, Kenmore, WA, USA. Electronic address: pcostamallen@bastyr.edu.
2: Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
3: Booth Gardner Parkinson's Care Center, Evergreen Health, Kirkland, WA, USA.
4: Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
5: Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
6: Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
7: Virginia Mason Medical Center, Seattle, WA, USA.
8: University of California San Diego, Department of Family & Preventive Medicine, La Jolla, USA.

Articles cited by this

Identification of the haemoglobin scavenger receptor. Nature (2001) 7.05

Ferritin in serum. Clinical and biochemical implications. N Engl J Med (1975) 4.51

Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem (1996) 4.02

Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging (2001) 3.36

Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol (2007) 2.53

Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet (1982) 2.42

Structure-function analysis of the antioxidant properties of haptoglobin. Blood (2001) 2.17

Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology (2009) 2.09

Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood (2010) 2.02

A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology (2005) 2.00

Molecular heterosis: a review. Mol Genet Metab (2000) 1.59

A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology (1988) 1.57

Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol (2002) 1.45

The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol (2014) 1.35

Regulated secretion of glycosylated human ferritin from hepatocytes. Blood (2003) 1.29

Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat Disord (2010) 1.18

Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med (2013) 1.18

Altered systemic iron metabolism in Parkinson's disease. Neurology (1997) 1.11

The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin Chem (2000) 1.07

The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet (2008) 1.04

Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J Neural Transm (Vienna) (1998) 1.00

Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci (2004) 0.98

Blood donations, iron stores, and risk of Parkinson's disease. Mov Disord (2006) 0.98

Association between lifetime cigarette smoking and lewy body accumulation. Brain Pathol (2009) 0.95

Iron and ferritin in inflammation and cancer. Adv Inorg Biochem (1994) 0.95

Calcium, copper, iron, magnesium, silicon and zinc content of hair in Parkinson's disease. J Trace Elem Med Biol (2005) 0.95

ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control. Parkinsonism Relat Disord (2007) 0.91

THE EFFECT OF HAPTOGLOBIN POLYMER SIZE ON HEMOGLOBIN BINDING CAPACITY. Vox Sang (1965) 0.89

Peripheral iron metabolism in patients with Parkinson's disease. J Neurol Sci (1994) 0.80